Who is eligible for clinical trial NCT07537153?

Participants must meet the protocol's inclusion criteria for Osteoarthritis. The stated age range is 40 Years to 80 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07537153 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-11

Genicular Artery Embolization for Knee Osteoarthritis (NCT07537153)

Genicular Artery Embolization for Patients With Mild-To-Moderate Knee Osteoarthritis

🟢 Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: Northwestern University

🩺 Plain-English Summary (8th-Grade Level)

Patients will be asked to take part in this research study because they have mild-to-moderate knee osteoarthritis (OA) and were referred clinically for a procedure called Genicular Artery Embolization (GAE). Osteoarthritis is the most common form of arthritis. It occurs when the protective cartilage that cushions the ends of the bones wears down over time. The symptoms of OA include pain or aching, stiffness, decreased range of motion, and swelling. The purpose of this study is to evaluate the safety and effectiveness of GAE for the treatment of knee pain attributed to OA. Research participants will be in this research study for about 3 years. The study includes a screening visit, GAE procedure, and six follow-up visits. At the screening visit, a review of their medical history, demographics, and medications will be collected; physical examination will be completed; knee x-ray will be done; and two questionnaires on your knee pain will be administered. The GAE procedure will involve receiving sedation or medication to help them relax, lidocaine injected under the skin in the area of the body where catheters will be inserted into one of your arteries and then using x-ray, a catheter will be directed to the arteries supplying the lining of the knee. Then tiny microspheres will be injected into the artery to decrease the blood supply to this knee joint tissue. The follow-up visits up to 12 months will include a focused physical examination of the treated knee, documentation of medications, and two questionnaires will be administered. The follow-up visits at year 2 and 3 will include documentation of medications and any new treatments for OA as well as completion of two questionnaires. Follow-up visits maybe conducted in clinic or remotely.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (13 items).

Location: Northwestern University — Chicago, Illinois

Age range: 40 Years to 80 Years

🧪 Interventions in This Study

Embosphere Microspheres (DEVICE)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age 40-80 years
Mild-to-moderate knee OA as determined by radiographs demonstrating Kellgren- Lawrence grade 2-3
Self-reported pain of at least 5/10 VAS questionnaire
Failure of conservative therapy, such as pain medications, for at least 3 months
Patient must understand and sign the informed consent
Patient can comply with the proposed follow-up schedule
Patient can follow the post-operative management

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
History of rheumatoid arthritis
Renal insufficiency precluding angiography (GFR \< 50 mL/min)
Irreversible coagulopathy
Previous knee arthroplasty on the intended knee
Existing knee joint infection
Kellgren-Lawrence grade 1 or 4
Severe atherosclerosis as manifest by claudication and/or diminished peripheral pulses
Life expectancy \< 6 months
Infectious arthritis
Allergy to iodinated contrast resulting in anaphylaxis
Pregnant or interested in becoming pregnant three months from the date of the GAE procedure

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Northwestern University — Chicago, Illinois

📞 Contact the Study Coordinator

Phone: (312) 695-9121

Email: r-lewandowki@northwestern.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Osteoarthritis

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip — Grove City, Pennsylvania
FORCE-TJR: Improving Orthopedic Outcomes Through a National TJR Registry — Worcester, Massachusetts
Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder System — San Francisco, California
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN)) — Gainesville, Florida
Activating SilverSneakers Benefits for Seniors With Osteoarthritis — Hershey, Pennsylvania

Explore by condition: All Osteoarthritis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗